

Return on Innovation



Global health R&D delivers for Ohio



US government (USG) investment in global health R&D has delivered

\$168.5 million
to Ohio research institutions*

2,200+ new jobs
for Ohio†

Ohio's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
Case Western University	\$99.6 million
Ohio State University	\$36.4 million
Cincinnati Children's Hospital Medical Center	\$14.9 million
University of Toledo	\$6.5 million
Cleveland Clinic Lerner College of Medicine	\$3.3 million
Cleveland State University	\$3.3 million
Ohio University	\$1.5 million

Neglected diseases in Ohio‡

HIV diagnoses	9,046
Tuberculosis cases	1,464
Malaria cases	285
West Nile cases	251
Zika cases	86

Ohio industry in global health R&D


AstraZeneca: West Chester
Biosortia Pharma: Dublin
Clinical Research Management: Hinkley
Metallopharm: Powell
Quidel: Athens

Global health R&D at work in the Buckeye State



Cincinnati Children's Hospital Medical Center led early stage clinical trials of two *Shigella* vaccine candidates. Worldwide, *Shigella* causes more than 150 million cases of severe diarrhea and dysentery annually, including 500,000 cases in the United States, and kills more than 1 million people each year, most of whom are young children in low-income countries. Antibiotics are the standard treatment, but drug-resistant strains are emerging, and no vaccine is yet available.

Ohio's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES*

89¢ of every dollar
the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, Malaria cases 2008-2014, West Nile virus disease cases 2008-2016, Zika virus disease cases 2015-2017.

§Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.